Harper says that Amgen is aware of the mediocre results for IGF1 drugs elsewhere, but decided to go ahead in pancreatic cancer because of strong results it got in second stage trials, where its drug delayed the progression of the disease by about four months.
The second is The Diabetes Prevention Program, which has illustrated that it is indeed possible to prevent the progression of pre-diabetes to diabetes.